Earnings summaries and quarterly performance for Annovis Bio.
Executive leadership at Annovis Bio.
Board of directors at Annovis Bio.
Research analysts covering Annovis Bio.
Recent press releases and 8-K filings for ANVS.
Annovis Bio, Inc. Provides Clinical Trial and Financial Update
ANVS
New Projects/Investments
Guidance Update
- Annovis Bio, Inc. reported a cash balance of $19 million as of December 31, 2025, with $0 debt, having raised $40 million in 2025.
- The company's lead drug candidate, buntanetap, is currently in a Pivotal Phase 3 trial for early Alzheimer's disease (AD), which has enrolled 40% of its 760 participants, with full recruitment estimated for Spring 2026.
- An Open Label Extension (OLE) study for Parkinson's disease (PD) has begun screening patients, and the company received FDA guidance for a new Parkinson's disease dementia (PDD) study.
- Buntanetap has demonstrated significant cognitive improvement across AD and PD and potential disease-modifying activity.
Jan 28, 2026, 9:28 PM
Annovis Bio Reports Q3 2025 Financial Results and Corporate Updates
ANVS
Earnings
CFO Change
New Projects/Investments
- Annovis Bio reported cash and cash equivalents of $15.3 million as of September 30, 2025, and a basic and diluted net loss per common share of $0.37 for the three months ending September 30, 2025.
- The pivotal Phase 3 Alzheimer's study (NCT06709014) is fully activated across all 84 clinical sites in the U.S., with the first patients having completed the 6-month treatment period.
- The company announced encouraging biomarker results from its Phase 2/3 AD trial, showing reductions in neuroinflammation and neurodegeneration, and successfully transferred all patents to the new crystal form of buntanetap, securing intellectual property protection through 2046.
- Mark Guerin was appointed as Chief Financial Officer in September.
Nov 12, 2025, 10:49 PM
Annovis Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
ANVS
Earnings
CFO Change
New Projects/Investments
- Annovis Bio reported a net loss per common share of $0.37 for the third quarter of 2025, an improvement from $0.97 in the same period last year.
- As of September 30, 2025, cash and cash equivalents totaled $15.3 million, with operations funded through the third quarter of 2026.
- The pivotal Phase 3 Alzheimer's study is on track, with all 84 clinical sites activated and recruiting, and the first patients have completed the 6-month treatment period.
- In September, Mark Guerin was appointed CFO, and the company secured intellectual property protection for its new crystal form of buntanetap through 2046 by transferring all patents.
Nov 12, 2025, 1:00 PM
Annovis Bio, Inc. Announces Registered Direct Offering
ANVS
- Annovis Bio, Inc. (ANVS) entered into agreements for a registered direct offering of 1,670,732 shares of common stock at an offering price of $2.05 per share.
- The offering is expected to generate approximately $3.425 million in gross proceeds, which the company plans to use for the continued clinical development of Buntanetap in a Phase 3 study for Alzheimer's disease, working capital, and general corporate purposes.
- In connection with the offering, 83,537 Placement Agent Warrants were issued to H.C. Wainwright & Co., LLC, with an exercise price of $2.5625 per share.
- The offering is expected to close on or about October 28, 2025.
Oct 28, 2025, 9:07 PM
Annovis Bio Announces Registered Direct Offering
ANVS
- Annovis Bio, Inc. has entered into definitive agreements for a registered direct offering of 1,670,732 shares of its common stock.
- The shares are priced at $2.05 per share, matching the closing price on NYSE on October 24, 2025.
- The offering is expected to generate approximately $3.4 million in aggregate gross proceeds for the Company.
- The net proceeds from the offering are intended for working capital and general corporate purposes.
- The offering includes participation from Michael Hoffman, the Company's Chairman, and Dr. Maria Maccecchini, the Company's Chief Executive Officer.
Oct 27, 2025, 12:00 PM
Annovis Bio Announces $6 Million Registered Direct Offering
ANVS
New Projects/Investments
- Annovis Bio, Inc. announced a registered direct offering of common stock and pre-funded warrants, expecting to raise approximately $6 million in gross proceeds.
- The offering includes the sale of 3,150,000 shares of common stock and 850,000 pre-funded warrants at a purchase price of $1.50 per share (or pre-funded warrant).
- The net proceeds are designated for working capital, general corporate purposes, and specifically for the Phase 3 clinical development of Buntanetap for Alzheimer's disease.
- The offering is anticipated to close on or about October 14, 2025.
- H.C. Wainwright & Co. is acting as the exclusive placement agent, receiving a 7.0% cash fee of the gross proceeds and warrants to purchase up to 200,000 shares of common stock with an exercise price of $2.20 per share.
Oct 14, 2025, 9:19 PM
Annovis Bio Announces $6 Million Registered Direct Offering
ANVS
- Annovis Bio has entered into definitive agreements for a registered direct offering to sell 4,000,000 shares of its common stock (or pre-funded warrants) at a purchase price of $1.50 per share.
- The offering is expected to generate approximately $6 million in aggregate gross proceeds for the company.
- The closing of the offering is anticipated to occur on or about October 13, 2025.
- The net proceeds from the offering are intended for working capital and general corporate purposes.
Oct 10, 2025, 12:31 PM
Annovis Bio Announces Positive Biomarker Data for Buntanetap in Alzheimer's Patients
ANVS
New Projects/Investments
- Annovis Bio announced new biomarker data from its Phase 2/3 AD study for buntanetap, demonstrating its ability to attenuate inflammation and improve cellular health in Alzheimer's patients.
- The analysis revealed buntanetap reduced key inflammatory markers (IL-5, IL-6, S100A12, IFN-γ, IGF1R) and decreased NFL levels, indicating improved cellular integrity and neuronal health.
- These positive responses were observed in all patients with positive pTau217 plasma levels, including those with mild and moderate stages of the disease, suggesting potential disease-modifying effects.
- Buntanetap is currently being evaluated in a pivotal Phase 3 trial in early AD (NCT06709014), which is actively enrolling and treating patients across the U.S..
- Full biomarker data will be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference from December 1-4, 2025.
Oct 9, 2025, 11:30 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more